Bin Zhao, People's Republic of China
Organ Transplantation Institute of Xiamen University
Immunosuppressive effect of arsenic trioxide (A2O3) on xeno-islet transplantation
Bin Zhao1, Lumin Wang1, Junjie Xia1, Zhongquan Qi1.
1Medical College, Xiamen University, Organ Transplantation Institute, Xiamen, People's Republic of China
Background: The immunorejection of islet transplantation has been a widely concerned problem in clinical practice, which hinder its popularization. And our previous research has been demonstrated that arsenic trioxide (As2O3) has the effect of immunosuppression and prolonging islet allograft survival. Therefore, according to previous research, we studied whether As2O3 has the similar effect and mechanism on islet transplantation.
Method: Apply streptozocin (STZ) in C57BL / 6 mice to induce with type 1 diabetes, then establish heterogeneous islet transplantation model. These model rice are divided into different groups by therapeutic regimen, and recycle graft, blood and tissue samples of recipient rice, then conduct cross comparison between groups for vitro and vivo experiment results. Finally, analyze effect of As2O3 for allgograft and receptor’s immune system in the heterogeneous islet transplantation.
Conclusion: The result has shown that As2O3 can lower posttransplantation cellular immune level, improve the level of Foxp3+ regulatory T cells and lower part of the serum antibody level to prolong allograft survival. At the same time, our study has found As2O3 has obvious synergistic effect with leflunomide.
Keyword: Heterogeneous islet transplantation;Immunosuppressants; As2O3
References:
[1] Cooke, D.W. and L. Plotnick, Type 1 diabetes mellitus in pediatrics. Pediatr Rev, 2008. 29(11): p. 374-84; quiz 385.
[2] Chiang, J.L., et al., Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care, 2014. 37(7): p. 2034-54.
[3] Knip, M., et al., Environmental triggers and determinants of type 1 diabetes. Diabetes, 2005. 54 Suppl 2: p. S125-36.
[4] Shapiro, A.M., C. Ricordi, and B. Hering, Edmonton's islet success has indeed been replicated elsewhere. Lancet, 2003. 362(9391): p. 1242.
[5] Hirshberg, B., et al., Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care, 2003. 26(12): p. 3288-95.
[6] Robertson, R.P., Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med, 2004. 350(7): p. 694-705.
[7] Piemonti, L., et al., Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes, 2013. 62(5): p. 1656-64.
[8] Lacy, P.E. and M. Kostianovsky, Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes, 1967. 16(1): p. 35-9.
[9] Kemp, C.B., et al., Transplantation of isolated pancreatic islets into the portal vein of diabetic rats. Nature, 1973. 244(5416): p. 447.
[10] Scharp, D.W., et al., Transplantation of islets of Langerhans in diabetic rhesus monkeys. Surgery, 1975. 77(1): p. 100-5.
[11] Tzakis, A.G., et al., Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet, 1990. 336(8712): p. 402-5
[12] Shapiro, A.M., et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000. 343(4): p. 230-8.
[13] Healy, D.G., et al., Heart transplant candidates: factors influencing waiting list mortality. Ir Med J, 2005. 98(10): p. 235-7.
[14] Tisato, V. and E. Cozzi, Xenotransplantation: an overview of the field. Methods Mol Biol, 2012. 885: p. 1-16.
[15] van der Windt, D.J., et al., Clinical islet xenotransplantation: how close are we? Diabetes, 2012. 61(12): p. 3046-55.
[16] Platt, J.L. and M. Cascalho, New and old technologies for organ replacement. Curr Opin Organ Transplant, 2013. 18(2): p. 179-85.
[17] Bailey, L.L., et al., Baboon-to-human cardiac xenotransplantation in a neonate. JAMA, 1985. 254(23): p. 3321-9.
[18] Michler, R.E., Xenotransplantation: risks, clinical potential, and future prospects. Emerg Infect Dis, 1996. 2(1): p. 64-70.
[19] Dooldeniya, M.D. and A.N. Warrens, Xenotransplantation: where are we today? J R Soc Med, 2003. 96(3): p. 111-7.
[20] Taylor, A.L., et al., Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation, 2007. 83(7): p. 931-7.
[21] Candinas, D. and D.H. Adams, Xenotransplantation: postponed by a millennium? QJM, 2000. 93(2): p. 63-6.
Lectures by Bin Zhao
| When | Session | Talk Title | Room |
|---|---|---|---|
|
Sat-20 17:00 - 18:30 |
Cell Transplant and Xenotransplantation Posters | Immunosuppressive Effect of Arsenic Trioxide (A2O3) on Xeno-Islet Transplantation | Hall 5FG-Level 5 |